Individualization of anticoagulation therapy of warfarin based on pharmacogenetic information
Project/Area Number |
20590548
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Meiji Pharmaceutical University |
Principal Investigator |
TAKAHASHI Harumi Meiji Pharmaceutical University, 薬学部, 教授 (20211344)
|
Co-Investigator(Kenkyū-buntansha) |
ECHIZEN Hirotoshi 明治薬科大学, 薬学部, 教授 (00191924)
|
Co-Investigator(Renkei-kenkyūsha) |
GOTO Shinya 東海大学, 医学部, 教授 (50225653)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | ワルファリン / 個体差 / 応答性 / CYP2C9 / VKORC1 / 遺伝子多型 / INR / 抗凝固効果 / 投与前凝固活性 / VKORC1*2 / CYP4F2*3 |
Research Abstract |
Influences of CYP2C9^*3 and VKORC1^*2 polymorphisms on the inter-individual differences in anticoagulation responses and maintenance dosages of warfarin were investigated in Asian (Japanese & Chinese) patients by performing the retrospective and prospective clinical studies. As a results, a CYP2C9^*3 mutation and a body weight, and VKORC1^*2 mutation and an age were extracted as pharmacokinetic and pharmacodynamic covariates, respectively.
|
Report
(4 results)
Research Products
(43 results)
-
[Journal Article] Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer2010
Author(s)
Ajima H, Ogata H, Fujita K, Miwa K, Sunakawa Y, Mizuno K, Ishida H, Yamashita K, Nakayama H, Kawara K, Takahashi H, Sasaki Y
-
Journal Title
Jpn.J.Clin.Oncol. 40
Pages: 634-638
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-